Table 1
Patient Demographics and Clinical Indications
| Patient Demographics | Clinical Indications for BoNT | ||
|---|---|---|---|
| Female sex, n (%) | 43 (63) | Dystonia patients (n = 44)a | |
| Age, mean (SD) | 60 (15) | Cervical dystonia | 31 |
| Education, mean (SD) | 14 (3) | Upper extremity dystonia | 14 |
| Mean duration of follow-up, months (SD) | 23 (20) | Lower extremity dystonia | 14 |
| Patients receiving DBS after BoNT, n (%) | 9 (13) | Jaw opening/closing dystoniab | 7 |
| Blepharospasmb | 6 | ||
| Truncal dystonia | 2 | ||
| Other indicationsb: migraine | 3 | ||
| sialorrhea | 3 | ||
| Spasticity patients (n = 24) | |||
| Focal upper extremity spasticity only | 9 | ||
| Focal lower extremity spasticity only | 7 | ||
| Combined | 8 |
Abbreviations: BoNT, Botulinum Neurotoxin Therapy; DBS, Deep Brain Stimulation; SD, Standard Deviation.
Table 2
Adverse Effects and Reasons for Discontinuing BoNT
| Adverse effects reported after first therapy of OnaA > 400 Ua | Reasons for patients discontinuing BoNT | ||
|---|---|---|---|
| Headache | 1 | Lost to follow-up | 13 |
| Bruising | 3 | Passed away or transferred to hospice | 7 |
| Dysphagia | 2 | Lack of benefit | 6 |
| Muscle weakness | 3 | Moved away | 5 |
| Head drop | 3 | Otherb | 3 |
| Flu-like symptoms | 2 | Insurance barriers | 2 |
| Side effects | 1 | ||
| Received DBS | 1 |